title: Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease.
abstract: Primary melanomas that form within the eye have a unique pattern of disease progression as compared with melanomas that form within the skin. A high percentage of patients (approximately 50%) develop metastatic tumors that occur predominately in the liver. An unusual characteristic of ocular melanomas is the prolonged disease-free interval that extends for many years between the development of primary and metastatic tumors. It is estimated that the shortest interval between dissemination of tumor cells from the eye and the appearance of clinically detectable metastases is 6 years. A recent report indicated that fresh uveal melanoma tissue and metastatic tumor biopsies failed to express melanoma antigen gene (MAGE)-1, MAGE-2, or MAGE-3. In the present study, we examined the expression of MAGE genes on fresh and cultured tumor cells obtained from an ocular melanoma patient during different stages of progressive disease. MAGE gene expression was determined by reverse transcription-polymerase chain reaction using MAGE-1, MAGE-2 and MAGE-3 specific primers. Our results demonstrate that primary ocular tumor tissue and cultured tumor cells both express significant levels of MAGE-1, 2, and 3 at the time of enucleation. A high percentage of tumor cells within the primary tumor appear to express MAGE as demonstrated by consistent MAGE expression in 16 tumor cell clones. Metastatic liver tumors that developed 3 years after enucleation and 18 years after the initial formation of the primary tumor also expressed high levels of MAGE-1, -2, and -3. MAGE was expressed on fresh tumor tissue from a single biopsy and cultured tumor cells obtained from three of four different metastatic tumor nodules. When the MAGE-negative metastatic tumor cells were treated with the demethylating agent 5-Aza-2-Deoxycytidine (5-Aza-dC), transcription of MAGE-1 was restored, indicating the MAGE genes were not deleted. Our results demonstrate that in some patients, MAGE genes are expressed on primary and metastatic ocular melanomas.
authors.affiliation: The Schepens Eye Research Institute and The Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA.
authors.forename: P W
authors.initials: PW
authors.lastname: Chen
authors.forename: T G
authors.initials: TG
authors.lastname: Murray
authors.forename: T
authors.initials: T
authors.lastname: Uno
authors.forename: M L
authors.initials: ML
authors.lastname: Salgaller
authors.forename: R
authors.initials: R
authors.lastname: Reddy
authors.forename: B R
authors.initials: BR
authors.lastname: Ksander
mesh_terms: D000951:Antigens, Neoplasm; D001374:Azacitidine / Q000031:analogs & derivatives / Q000494:pharmacology; D002999:Clone Cells; D000077209:Decitabine; D018450:Disease Progression; D005134:Eye Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000556:secondary; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008545:Melanoma / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary*; D058950:Melanoma-Specific Antigens; D009362:Neoplasm Metastasis / Q000235:genetics; D009363:Neoplasm Proteins / Q000235:genetics* / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D000951:Antigens, Neoplasm; C072011:MAGEA1 protein, human; C072013:MAGEA3 protein, human; C072012:MAGEB2 protein, human; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D000077209:Decitabine; D001374:Azacitidine